Advances in the treatment of herpesvirus infection: The role of famciclovir

Clinical Therapeutics

Volumn 20, Issue 4, 1998, Pages 661-670

  Tyring, Stephen K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Famciclovir; Genital herpes; Herpes simplex virus 2; Herpes zoster; Varicella zoster virus

Indexed keywords

FAMCICLOVIR;

ANTIVIRAL ACTIVITY; GENITAL HERPES; HERPES; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; REVIEW; VARICELLA ZOSTER VIRUS;

EID: 0031665067     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80129-X     Document Type: Review

References (45)

1. Crumpacker C. The pharmacological profile of famciclovir. Semin Dermatol. 1996; 15(Suppl 1): 14-26.
2. Fowles SE, Pue MA, Pierce D, et al. Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir. Br J Clin Pharmacol. 1992;35:450.
3. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother. 1993;4(Suppl 1):47-55.
4. ®. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Data; 1997:1167-1169.
5. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595-605.
6. Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994;33:119-127.
7. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29-37.
8. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother. 1993;4:67-84.
9. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992;36:2747-2757.
10. Bacon TH, Gilbert J, Howard BA, Standing-Cox R. Inhibition of varicella-zoster virus by penciclovir in cell culture and mechanism of action. Antiviral Chem Chemother. 1996;7:71-78.
11. Data on file. Philadelphia. Pa: SmithKline Beecham; 1998.
12. Boon RJ, Saltzman R, Atkinson GF. The clinical safety experience with famciclovir. Presented at the 1996 meeting of the American Association for the Study of Liver Diseases; Chicago, Illinois. Abstract 623.
13. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38:2454-2457.
14. Straus SE. Shingles. Sorrows, salves, and solutions. JAMA. 1993;269:1836-1839.
15. Preblud SR, Orenstein WA, Bart KJ. Varicella: Clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis. 1984;3:505-509.
16. McKendrick M. Challenge of herpes zoster infections. Presented at Third Congress of the European Academy of Dermatology and Venereology; Copenhagen, Denmark; 1993. Abstract.
17. Straus SE, Ostrove JM, Inchauspe G, et al. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med. 1988;108: 221-237.
18. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: Clinical review and current management. Ann Neurol. 1986;20:651-664.
19. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571-575.
20. Dolin R, Reichman RC, Mazur MH, Whitley RJ. Herpes zoster-varicella infection in immunosuppressed patients. Ann Intern Med. 1978;89:375-388.
21. Loeser JD. Herpes zoster and postherpetic neuralgia. Pain. 1986;25:149-164.
22. Friedman-Kien AE, Lafleur FL, Gendler E, et al. Herpes zoster: A possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol. 1986; 14:1023-1028.
23. Whitley RJ. Varicella-zoster virus infection. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill Inc.; 1994:787-790.
24. Burgoon CF, Burgoon JS. The natural history of herpes zoster. JAMA. 1957;164: 265-269.
25. Rowbotham MC. Treatment of postherpetic neuralgia. Semin Dermatol. 1992;11: 218-225.
26. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:89-96.
27. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4:241-246.
28. Straus SE, Rooney JF, Sever JL, et al. Herpes simplex virus infection: Biology, treatment, and prevention. Ann Intern Med. 1985;103:404-419.
29. Corey L. The current trend in genital herpes. Sex Transm Dis. 1994;21(Suppl 2): S38-S44.
30. Sacks SL. Genital herpes simplex virus infection and treatment. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD, eds. Clinical Management of Herpes Viruses. Washington, DC: IOS Press; 1995:55-74.
31. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Ann Intern Med. 1983; 98:958-972.
32. Knodel LC, Roush MK. Sexually transmitted diseases. In: Knodel LC, ed. Pharmacotherapy: A Pathophysiological Approach. Norwalk, Conn: Appleton & Lange; 1993:1717-1738.
33. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. NEJM. 1987;316:1444-1449.
34. Mertz GJ. Genital herpes simplex virus infections. Med Clin North Am. 1990;74: 1433-1454.
35. Corey L, Wald A, Davis LG. Subclinical shedding of HSV: Its potential for reduction by antiviral therapy. In: Mills J, ed. Antiviral Chemotherapy 4. New York: Plenum Press; 1996.
36. Sacks SL, Martel A, Aoki F, et al. Clinicinitiated treatment of recurrent genital herpes using famciclovir: Results of a Canadian multicenter study. Presented at Sixth International Congress for Infectious Diseases; Prague, Czechoslovakia; 1994.
37. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial. JAMA. 1996;276:44-49.
38. Mertz G, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. Arch Intern Med. 1997;157: 343-349.
39. Mindel A, Faherty A, Carney O, et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet. 1988;8591:926-928.
40. Tyring SK, International Valacyclovir HSV Study Group. Once-daily valacyclovir for suppression of genital herpes - results from a large, international, controlled study. Presented at American Academy of Dermatology meeting; March 21-26, 1997; San Francisco, Calif.
41. Field HJ, Thackray AM. The effects of delayed-onset chemotherapy using famciclovir or valacyclovir in a murine immunosuppression model for HSV-1. Antiviral Chem Chemother. 1995;6:210-216.
42. Field HJ, Tewari D, Sutton D, Thackray AM. Comparison of efficacies of famciclovir and valacyclovir against herpes simplex virus type I in a murine immunosuppression model. Antimicrob Agents Chemother. 1995;39:1114-1119.
43. Thackray AM, Field HJ. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis. 1996; 173:291-299.
44. Ahmed A, Woolley PD. Comparison of famciclovir and acyclovir in first episodes of genital herpes: Possible effect on latency. Presented at the European Conference on Herpesviruses; Paris, France; 1996.
45. Loveless M, Sacks SL, Harris JRW. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Pract. 1997;6(Suppl 1):S12-S16.